LeMaitre Vascular, Inc. $LMAT Stake Reduced by SG Americas Securities LLC

SG Americas Securities LLC cut its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 51.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,204 shares of the medical instruments supplier’s stock after selling 28,605 shares during the period. SG Americas Securities LLC’s holdings in LeMaitre Vascular were worth $2,970,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. MAI Capital Management bought a new position in shares of LeMaitre Vascular during the third quarter worth about $38,000. Geneos Wealth Management Inc. lifted its position in LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 398 shares during the last quarter. EverSource Wealth Advisors LLC acquired a new position in LeMaitre Vascular during the 2nd quarter valued at about $47,000. GAMMA Investing LLC boosted its stake in LeMaitre Vascular by 32.7% during the 4th quarter. GAMMA Investing LLC now owns 727 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 179 shares during the period. Finally, Quarry LP grew its position in LeMaitre Vascular by 267.2% in the 3rd quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock worth $64,000 after purchasing an additional 529 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on LMAT shares. Wall Street Zen lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, June 20th. Wells Fargo & Company increased their price objective on LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a report on Wednesday, May 6th. Freedom Capital upgraded LeMaitre Vascular to a “hold” rating in a research report on Tuesday, March 31st. Zacks Research raised LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 13th. Finally, Weiss Ratings upgraded LeMaitre Vascular from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, May 20th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, LeMaitre Vascular currently has an average rating of “Moderate Buy” and an average target price of $112.60.

LeMaitre Vascular Stock Down 0.0%

LMAT opened at $95.96 on Wednesday. LeMaitre Vascular, Inc. has a one year low of $79.00 and a one year high of $118.01. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32. The stock’s fifty day moving average is $99.49 and its 200-day moving average is $96.91. The company has a market capitalization of $2.19 billion, a PE ratio of 35.41, a P/E/G ratio of 2.67 and a beta of 0.54.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.02. The business had revenue of $66.55 million during the quarter, compared to analysts’ expectations of $66.67 million. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The company’s quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter last year, the business posted $0.48 earnings per share. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. On average, equities analysts predict that LeMaitre Vascular, Inc. will post 3 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, June 4th. Stockholders of record on Thursday, May 21st were given a dividend of $0.25 per share. The ex-dividend date was Thursday, May 21st. This represents a $1.00 annualized dividend and a dividend yield of 1.0%. LeMaitre Vascular’s dividend payout ratio (DPR) is 36.90%.

Insider Transactions at LeMaitre Vascular

In related news, Director Bridget A. Ross sold 5,044 shares of the stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $111.10, for a total transaction of $560,388.40. Following the completion of the sale, the director directly owned 3,942 shares of the company’s stock, valued at $437,956.20. This represents a 56.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Trent G. Kamke sold 2,928 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $107.00, for a total transaction of $313,296.00. Following the sale, the insider owned 3,749 shares of the company’s stock, valued at $401,143. The trade was a 43.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 54,453 shares of company stock valued at $5,906,174 in the last quarter. Insiders own 7.40% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.